Schizophrenia as a membrane lipid disorder which is expressed throughout the body.
Clinical, biochemical and genetic evidence now indicates that schizophrenia is a disorder of membrane phospholipid metabolism associated with increased loss of highly polyunsaturated fatty acids from membranes owing to enhanced activity of a phospholipase A2. This changes the properties of membranes throughout the body and is responsible for such physical abnormalities as reduced vasodilator responses to niacin and histamine and altered immunological functions. A modest membrane abnormality is likely to produce its most serious consequences in the brain, which requires the co-ordinated sequential and parallel activities of millions of neurons. The concept leads to testable proposals for relatively simple and safe treatment modalities.
Scotia Pharmaceuticals, Stirling, UK.
D F
DF
Horrobin
D016718:Arachidonic Acid / Q000378:metabolism / Q000627:therapeutic use; D004281:Docosahexaenoic Acids / Q000378:metabolism / Q000627:therapeutic use; D006801:Humans; D008563:Membrane Lipids; D010741:Phospholipases A / Q000037:antagonists & inhibitors / Q000378:metabolism; D054467:Phospholipases A2; D012559:Schizophrenia / Q000209:etiology* / Q000628:therapy
D008563:Membrane Lipids; D004281:Docosahexaenoic Acids; D016718:Arachidonic Acid; D010741:Phospholipases A; D054467:Phospholipases A2